The overall goal of this project is to establish new animal models that will reliably predict the efficacy and safety of human immunodeficiency (HIV-1) vectors in humans. A major impediment to achieving this goal are the species-specific restriction on HIV-1 infectivity. These species- specific restrictions occur at a post-entry level and therefore apply to HIV-1 lentiviral vectors pseudotyped with heterologous envelope glycoproteins. An understanding of the HIV-1 genomic determinants of these restrictions will allow the creation of HIV-1 vectors that are suitable for infection of commonly used non-human primates. The insights obtained in this study will assist the establishment of new animal models of HIV-1 infection and the testing of HIV-1 vectors.
The specific aims of the proposal are: 1) To adapt HIV-1 to replicate in monkey cell lines that exhibit progressively greater degrees of restriction against HIV-1 infection. 2) To characterize the changes in the adapted HIV-1 that are necessary and sufficient for replication in monkey cell lines. 3) To determine whether the adaptation-associated changes overcome the restrictions to HIV-1 infection in primary monkey cells and in some non- primate mammalian species. 4) To provide research-grade HIV-1 vectors to other investigators within the program.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL054785-06
Application #
6368219
Study Section
Special Emphasis Panel (ZHL1-CSR-C (S1))
Project Start
1995-09-30
Project End
2005-08-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
$284,242
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Huang, Min; Kennedy, Richard; Ali, Abdullah M et al. (2011) Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. DNA Repair (Amst) 10:1203-12
Kee, Younghoon; Kim, Jung Min; D'Andrea, Alan D et al. (2009) Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev 23:555-60
Chen, Clark C; Kennedy, Richard D; Sidi, Samuel et al. (2009) CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 8:24
Mirchandani, Kanchan D; McCaffrey, Ryan M; D'Andrea, Alan D (2008) The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst) 7:902-11
Davies, Jeff K; Gribben, John G; Brennan, Lisa L et al. (2008) Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 112:2232-41
Ansen, Sascha; Butler, Marcus O; Berezovskaya, Alla et al. (2008) Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res 14:6125-36
Kennedy, Richard D; Chen, Clark C; Stuckert, Patricia et al. (2007) Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117:1440-9
Butler, Marcus O; Lee, Jeng-Shin; Ansen, Sascha et al. (2007) Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13:1857-67
Li, Xing; Gold, Bert; O'hUigin, Colm et al. (2007) Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360:419-33
Wang, Xiaozhe; Kennedy, Richard D; Ray, Kallol et al. (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27:3098-108

Showing the most recent 10 out of 88 publications